{"preliminary_commentary":{"by_channel":{"x_thread":7,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03497767\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["osimertinib","stereotactic radiosurgery"],["osimertinib"]],"indication":"EGFR-mutated NSCLC with brain metastases","name":"OUTRUN","nct_id":"NCT03497767","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=outrun-nct03497767. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"OUTRUN","arms":[{"description":"80mg Osimerinib taken once daily","label":"Osimertinib","type":"EXPERIMENTAL"},{"description":"Upfront Stereotactic Radiosurgery (SRS) followed by 80mg Osimerinib taken once daily","label":"Stereotactic Radiosurgery + Osimertinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-04-30","type":"ACTUAL"},"conditions":["Metastatic Non Small Cell Lung Cancer"],"enrollment":{"count":40,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Osimertinib","otherNames":["Tagrisso"],"type":"DRUG"},{"name":"Stereotactic Radiosurgery (SRS)","otherNames":[],"type":"RADIATION"}],"last_update":"2024-05-31","lead_sponsor":"Trans Tasman Radiation Oncology Group","official_title":"A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-04-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Intracranial progression free survival at 12 months","timeFrame":"12 months post randomisation"}],"references":[{"citation":"Lee CK, Lefresne S, Soon YY, Robledo K, Nichol A, Sahgal A, Pinkham MB, Melosky B, Huang Y, McDermott R, Tham IWK, Parmar A, Tey JCS, Liu M, Solomon BJ, Sacher A, Leong CN, Laskin J, Koh WY, Menjak IB, Ang Y, Shultz DB, Low JL, Doherty M, Yong C, Lim MC, Tan AP, Soo RA, Hegi-Johnson F, Ho C. Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials. J Thorac Oncol. 2026 May;21(5):103549. doi: 10.1016/j.jtho.2026.01.001. Epub 2026 Jan 12.","pmid":"41534788","type":"DERIVED"}],"start_date":{"date":"2019-08-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases","url":"https://clinicaltrials.gov/study/NCT03497767"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/outrun-nct03497767"}